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Summary Ge(IV) phthalocyanine (GePc) with two axially ligated cholesterol moieties was prepared by
chemical synthesis and incorporated in a monomeric state into small unilamellar liposomes (CGP 55398).
Upon photoexcitation with light wavelengths around its intense absorption peak at 680 nm, GePc shows an
efficient photosensitising activity towards biological substrates through a mechanism which largely involves the
intermediacy of singlet oxygen. GePc injected systemically into mice bearing an intramuscularly implanted
MS-2 fibrosarcoma is quantitatively transferred to serum lipoproteins and localises in the tumour tissue with
good efficiency: at 24 h post injection the GePc content in the tumour is 0.74 and 1.87 lag per g of tissue with a
tumour/peritumoral ratio of 4.35 and 5.67 for injected doses of 0.76 and 1.52 mg kg-' respectively. At this
time the red-light irradiation of the GePc-loaded fibrosarcoma causes a fast and massive tumour necrosis
involving both malignant cells and blood vessels.
While photodynamic therapy (PDT) of tumours with 630 nm
light and the haematoporphyrin derivative Photofrin II is in
phase III clinical trials in several centres (Marcus, 1992),
intensive investigations aim at identifying second-generation
tumour-localising and -photosensitising agents which over-
come, at least in part, the present limitations of Photofrin.
This porphyrin has a heterogeneous chemical composition, a
limited selectivity of tumour targeting and a low efficiency of
light absorption in the clinically useful wavelength range
600-800 nm (Bonnett & Berenbaum, 1990). In this connec-
tion, phthalocyanines appear to possess favourable
physicochemical and spectroscopic properties (Ben-Hur &
Rosenthal, 1985; Spikes, 1986): the large tetraazaisoindole
macrocycle imparts a high degree of hydrophobicity to
phthalocyanines; hence, in the absence of charged peripheral
substituents (e.g. tri- or tetrasulphonated phthalocyanines),
the in vivo administration of these photosensitisers requires
the use of suitable delivery systems.
Recent biodistribution and tumour-photosensitising studies
with the liposome-incorporated Zn(II) and Ge(IV)
phthalocyanines (Reddi et al., 1990; Cuomo et al., 1991)
point out that these compounds are phototherapeutically
active at doses as low as 0.15 mg per kg body weight with an
enhanced selectivity of accumulation by tumour tissues;
moreover, the presence of peripheral alkoxy substituents
appears to accelerate the clearance of phthalocyanines from
healthy tissues, such as liver and spleen (Cuomo et al., 1991).
The pharmacokinetic behaviour of phthalocyanines can be
also modulated by an appropriate choice of axial ligands
occupying the fifth and sixth coordination position of the
centrally bound metal ion (Bellemo et al., 1992). In this
paper, we report our findings about the photodynamic pro-
perties of a newly synthesised liposome-incorporated Ge(IV)
phthalocyanine (GePc) that is devoid of lateral substituents
and bears two cholesterol moieties as axial ligands (see
Figure 1 for the chemical structure). Cholesterol is known to
be largely carried in the bloodstream by low-density serum
lipoproteins (LDLs), which in turn express a preferential
interaction with malignant cells through receptor-mediated
endocytotic processes (Goldstein et al., 1985). LDLs have
been proposed as tumour-specific vehicles of systemically
injected photosensitisers (Jori, 1992a). Thus, the prebinding
of cholesterol to the phthalocyanine molecule could hopefully
favour its association with LDL and potentiate its
phototherapeutic effectiveness.
Materials and methods
Phthalocyanine
Germanium(IV) phthalocyanine [bis-(diphenylcholesteryloxy-
siloxy)-germanium phthalocyanine] was synthesised as des-
cribed in detail by Capraro et al. (1993). The synthesis is
performed by condensation of dihydroxygermanium
phthalocyanine with diphenylcholesteryloxysilanol in boiling
dioxane. The last compound can be prepared by reacting
equimolar amounts ofdichlorodiphenylsilane, cholesterol and
pyridine in benzene. GePc is crystallised from
dichloromethane/hexane. Melting point, 274-276°C;
UV(CH2Cl2), 358 (63900), 678 (275700); PDMS, 1753.9 (M+);
NMR (CDC13), 9.50 (m), 8.34 (m), 6.70 (t), 6.29 (t), 4.91 (d),
4.63 (m), 2.1-0 (remaining H atoms). The incorporation of
Ge(IV) phthalocyanine into small unilamellar liposomes was
performed by the same procedure as published for zinc(II)
phthalocyanine-containing liposomes (Isele et al., 1993), with
the exception that tetrahydrofuran was used as solvent for
both the phthalocyanine derivative and the phospholipids.
Liposomes were prepared from mixing of the phospholipids
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC,
CGP 31 586) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine
(OOPS, CGP 31 524A) at a ratio of 9:1. The dye-to-lipid
ratio was 1:100. The organic solvents were removed by
tangential flow filtration against a 10-fold volume of lac-
tose-sodium chloride solution. The liposomal formulation
CGP 55 398 was freeze dried for storage and resuspended by
adding pyrogen-free water immediately before use. All
dosages (mg kg-') mentioned in the experimental studies
were related to the active ingredient GePc.
Chemicals
L-Tryptophan, 99% pure, was a product of Aldrich (Mil-
waukee, WI, USA). Sodium dodecyl sulphate (SDS, Merck,
Darmstadt, Germany) and D20 (99-100%, Merck) were
used as received. The chromatographic resin Bio-Gel A-5 m,
200-400 mesh, with 6% (w/v) agarose content was pur-
chased from Bio-Rad. Bicinchoninic acid (BCA) and the
accompanying protein assay reagent were obtained from
Pierce (Rockford, IL, USA). EDTA (Titriplex III) and
sodium azide were obtained from Merck. The organic
solvents were Merck products of at least spectrophotometric
grade.
Animals and tumours
Female Balb/c mice, 20-22 g body weight, were obtained
from Charles River (Como, Italy) and kept in standard cages
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Figure 1 Structure of GePc.
with free access to normal dietary chow and tap water. The
MS-2 fibrosarcoma was originally supplied by Istituto
Nazionale Tumori, Milan, Italy. For tumour implantation,
2 x I05 cells in 0.2 ml of sterile physiological solution were
intramuscularly injected into the right hind leg of the mouse;
the tumour grows at a rather aggressive rate, reaching an
external diameter of c. 0.8 cm on the seventh day. All phar-
macokinetic and phototherapeutic studies were performed at
7-8 days after tumour implantation, when no detectable
spontaneous tumour necrosis had generally occurred. When
necessary, mice were anaesthesised by i.p. injection of
Ketalar. New Zealand white rabbits, weighing c. 2.5 kg, were
purchased from Ditta Conigli (Padova, Italy) and maintained
in standard cages under regular diet for at least 3 days before
experiment.
In all cases, animal care was performed according to the
guidelines established by the Italian Committee for
Experiments on Animals.
Serum distribution studies
Healthy rabbits were i.v. injected with 0.76 mg kg-' GePc in
the right ear. At 2 h after injection c. 30 ml of blood was
taken, centrifuged at 3,000 r.p.m. for 10 min, and the plasma
was collected. One aliquot of plasma was diluted 20-fold with
2% aqueous SDS, and the GePc content was determined by
spectrophotofluorimetric analysis upon excitation at 620 nm:
the fluorescence emission in the 650-800 nm interval was
measured and converted into GePc concentration by inter-
polation with a calibration plot obtained with GePc solutions
at known concentrations in 2% SDS. The residual plasma
(7.0 ml) was brought to a density of 1.225 by addition of a
suitable amount of potassium bromide and centrifuged in an
SW41 swinging-bucket rotor (Beckman) for 40 h at 15C and
39,000 r.p.m. using an Ultra Centrikon T-2060 ultracent-
rifuge (Kontron Instruments). The top 2 ml of the centri-
fugate, which contains at least 95% of the lipoproteins
(Rudel et al., 1974), was collected and separated from the
bottom, which contains the heavier serum proteins, mainly
albumin and globulins. The two protein fractions (top and
bottom) were dialysed for 5 h against 250 ml of 0.9% sodium
chloride at pH 7.4, to which were added 0.01% EDTA and
0.01% sodium azide, with two changes of the dialysing solu-
tion during the initial 3 h. The amount of GePc associated
with the two protein fractions was determined by
fluorescence measurements as specified above.
The lipoprotein concentrate (1.5 ml) was applied to an
agarose chromatography column (1.5 x 90 cm) containing
Bio-Gel A-5 m, 200-400 mesh with 6% (w/v) agarose added.
The column was eluted with 0.9% aqueous sodium chloride
at pH 7.4, containing 0.01% EDTA and 0.01% sodium
azide; the flow rate was 5 ml h-'. The eluate was monitored
for its absorbance at 280 nm to follow the protein content.
The fractions corresponding to individual lipoprotein peaks,
namely VLDL, LDL and HDL, were pooled, assayed for the
GePc content by spectrophotofluorimetry and the apoprotein
content by reaction with bicinchoninic acid (Smith et al.,
1985); the latter value was converted into holoprotein content
by using the standard apoprotein percentages of each lipo-
protein in rabbit serum (Chapman, 1986).
Pharmacokinetic studies
The mice bearing an MS-2 fibrosarcoma were injected in the
femoral vein with 0.76 or 1.52 mgkg-' GePc. At predeter-
mined times after administration the mice were sacrificed by
prolonged exposure to ether vapours; the blood, tumour and
selected normal tissues (muscle, skin, liver, spleen, brain)
were rapidly taken. The blood was centrifuged to remove the
erythrocytes, and the plasma was diluted with 2% aqueous
SDS in order to obtain an absorbance lower than 0.1 at
680 nm; then the GePc concentration in the plasma was
calculated by spectrophotofluorimetric analysis as described
in the previous paragraph. Tissue specimens (c. 200mg) were
homogenised with a Polythron in 3 ml of 2% aqueous SDS.
After incubation for 1 h at room temperature under gentle
magnetic stirring, the homogenate was 10-fold diluted with a
chloroform-methanol binary mixture (1:2, v/v) and cent-PDT OF TUMOURS WITH A NEW GE PHTHALOCYANINE 819
rifuged for 10 min at 3,000 r.p.m.; the supernatant was col-
lected and analysed for GePc content by fluorescence spect-
roscopy, using a calibration plot built with known concentra-
tions of GePc in the same solvent mixture.
Control studies showed that our extraction procedure
recovers at least 90% of tissue-bound phthalocyanine.
Moreover, no GePc-type fluorescence was observed in tissues
from uninjected mice.
Experimentalphotodynamic therapy
At 24 h after i.v. injection of 0.76 or 1.52 mg kg-' GePc, the
tumour area was exposed to 600-700 nm light, isolated from
the emission of a 250 W quartz/halogen lamp. The light
source (Teclas, Lugano, Switzerland) was equipped with a
parabolic reflector focusing the emission into a series of
infrared and bandpass filters; the beam was piloted into a
bundle of optical fibres, whose tip was positioned at a dis-
tance of 1 cm from the tumour surface. The lamp was
operated at a dose rate of 130 mW cm-2 for a totally
delivered light dose of 150 Jcm2. Under these irradiation
conditions, no tumour response was observed in mice which
had received no photosensitiser.
At different time intervals after the end of PDT, groups of
five mice at each time were sacrificed, the tumour was
excised, fixed in formalin and the extent of the necrotic area
was evaluated according to the procedure described by Reddi
et al. (1987).
In a different set of experiments, groups of three mice
treated with the above irradiation protocol at 24 h after
injection of 0.76mgkg-' GePc were sacrificed at 30min,
90min, 3 h and 8 h after the end of PDT. Small specimens
(c. 1 mm3) of tumour tissue were quickly removed, fixed for
2 h at 4°C in 3% glutaraldehyde, buffered with 0.1 M
cacodylate at pH 7.3, post-fixed for 1 h in 1% osmium tet-
roxide, cacodylate-buffered, dehydrated and embedded in an
Epon resin. The thin sections were doubly stained with
uranyl acetate and lead citrate and then examined with a
Hitachi H-600 electron microscope.
Spectroscopic measurements
Absorption spectra were recorded at room temperature using
a Perkin Elmer Lambda-2 spectrophotometer. Fluorescence
excitation and emission spectra were determined at 20 ± 1°C
with a Perkin Elmer MPF-4 spectrophotofluorimeter equip-
ped with a red-sensitive phototube. In the case of GePc the
strong overlap between the lowest energy absorption band
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and the fluorescence emission may cause optical artifacts
arising from inner filter and/or trivial reabsorption effects;
therefore, in order to minimise such effects, the GePc solu-
tions were always kept at an optical density lower than 0.05
at both the excitation and maximum absorption wavelengths.
The quantum yield of GePc fluorescence was calculated by
comparison of the area below the corrected emission spec-
trum for a 0.01 gM phthalocyanine solution in chloroform
with that of cresyl violet chosen as a fluorescence standard
(quantum yield 0.54 in methanol; Magde et al., 1979).
The kinetics of tryptophan photooxidation was studied by
following the decrease of the amino acid fluorescence in the
300-400 nm spectral range. The procedure was identical to
that described by Reddi et al. (1984). An aqueous dispersion
of GePc-containing liposomes (having an absorbance of 0.59
at 678 nm) to which a suitable tryptophan concentration
between 1 and 50lM was added was exposed to 600-700 nm
light using the same irradiation conditions and apparatus as
described for the phototherapeutic experiments. The GePc/
tryptophan system was placed in a quartz cuvette of 1 cm
optical path whose temperature was kept at 25 ± 1°C. At
predetermined irradiation times the cuvette was placed in the
cell holder of the spectrophotofluorimeter and the tryptophan
fluorescence was excited by 290 nm light. Control
experiments showed that under our experimental conditions
the fluorescence intensity is linearly correlated with tryp-
tophan concentration.
Results
Spectroscopic and in vitro irradiation studies
Cholesterol-bound GePc, when dissolved in a chloroform-
methanol binary mixture (1:2, v/v), exhibits a main absorp-
tion band peaking at 678 nm with a high extinction
coefficient (Figure 2a), as is typical of phthalocyanines lack-
ing peripheral substituents in the a-positions of the benzene
ring (van Lier & Spikes, 1989). Under these conditions, GePc
exists in a monomeric state, since it strictly follows the
Beer-Lambert law up to at least 1 mM. The fluorescence
emission spectrum of GePc (Figure 2b) shows a maximum at
684 nm, with a fluorescence quantum yield of 0.23, which is
independent of the excitation wavelength; moreover, the
excitation spectrum closely overlaps the absorption spectrum,
indicating that the emission originates only from the
monomeric GePc species. Aqueous liposomal dispersions of
GePc yield absorption and fluorescence spectra, which are
b
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Figure 2 Absorption (a) and 620 nm excited fluorescence emission (b) spectra of0.95JM GePc in chloroform-methanol (1:2, v/v)
solution. For the fluorescence measurements the solution was 3-fold diluted.820 A. SEGALLA et al.
identical to those shown in Figure 2 as regards the position
of the bands, the molar extinction coefficient and the
fluorescence yield. Thus, the phthalocyanine appears to be
100% monomeric in our liposomal preparation.
Exposure of GePc to 600-700 nm light, corresponding to
the series of absorption bands of this phthalocyanine in the
visible spectral range, causes a very slow decrease in the
overall absorbance: for an initial absorbance of 0.5 at
680 nm, the decrease is 13.5% (average of two independent
experiments) after delivery of c. 1,000 J cm-2 (1 h irradiation
at a dose rate of 300mWcm-2).
When photo-excitation of GePc in aqueous liposomal
suspensions is performed in the presence of the photo-
oxidisable substrate L-tryptophan, a time-dependent decrease
in the amino acid concentration is observed by following a
decrease in its fluorescence emission at 350 nm. The photo-
process follows first-order kinetics with respect to tryptophan
concentration, as previously observed for porphyrin-
sensitised tryptophan photo-oxidation (Reddi et al., 1984):
from the semilogarithmic plot describing the progress of the
reaction (Figure 3) one can deduce the rate constant
k = 2.85 x 10-3 S-l. When light water is replaced by D20 in
the solvent system, the rate constant of the photoprocess
undergoes a 39.8-fold enhancement. Moreover, the rate con-
stant does not change when tryptophan concentration is
varied within the 1-50jIM interval.
Transport ofGePc in rabbit serum
The distribution of liposome-delivered GePc among serum
proteins was analysed at 2 h after i.v. injection in healthy
rabbits. The protein pattern of rabbit serum is much closer to
that typical of human serum as compared with mouse or rat
serum (Gotto et al., 1986), hence the information thus
obtained can be more directly extrapolated to humans.
Previous studies (Ginevra et al., 1990) showed that in vitro
data obtained with human serum are substantially different
from in vivo data with rabbit serum; such a difference is likely
to reflect a dynamic process occurring in vivo in which the
photosensitiser is delivered from serum proteins to tissues.
The recovery of the phthalocyanine from the different
protein classes is shown in Table I. Clearly, GePc is almost
quantitatively transferred from the liposome vesicles to lipo-
proteins: less than 6% of the total GePc is found in the
heavy protein fraction, even if this fraction contains albumin
and globulins, which are by far the most abundant proteins
in serum. The highly preferential interaction of hydrophobic
photosensitisers with lipoproteins has been reported by
several investigators (see, for a recent review, Jori & Reddi,
1993). The distribution of GePc within the lipoprotein family
reflects the relative percentage of the single protein com-
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Figure 3 Effect of irradiation time on decrease in L-tryptophan
concentration photosensitised by GePc. [Tryptophan] = 5 LM;
[GePc] = 2.2gM; light wavelengths 600-700 nm.
Table I Distribution of GePc among plasma protein fractions
Sample Total ng of GePc per mg
analysed recovery (ng) of holoprotein
Plasma 64527
Lipoproteins 55636 (94%)
Heavy proteins 3587 (6%)
HDL 13364 (53%) 1995
LDL 6721 (27%) 1627
VLDL 5190 (20%) 1324
Rabbit plasma was obtained 2 h after
GePc.
injection of 0.76 mg kg-'
ponents, indicating a statistical partitioning of the
phthalocyanine between HDL, LDL and VLDL; this is fur-
ther supported by the observation that the affinity of GePc
for the three lipoprotein components, as expressed by referr-
ing the GePc recovery to one mg of each lipoprotein, is very
similar (Table I, last column).
Pharmacokinetic properties
The pharmacokinetic behaviour of GePc was examined for
two injected phthalocyanine doses, namely 0.76 and
1.52 mgkg-' b.w.; such doses are equivalent on a molar
basis to 0.25 and 0.5 mgkg-' Zn(II) phthalocyanine, which
has been extensively studied in our laboratories (Schieweck et
al., 1990; Jori et al., 1991). Thus a direct comparison between
the pharmacokinetic properties of the two phthalocyanines
would be possible.
At both injected doses, GePc is almost completely
eliminated from mouse serum within 1 week (Figure 4); the
clearance rate is particularly fast during the initial hours after
administration. Absorption and fluorescence analysis of
serum samples taken at 3 h after GePc injection shows spect-
ral features typical of the monomeric dye. At this time
interval the residual phthalocyanine in the bloodstream has
been completely transferred from liposomes to protein car-
riers (Polo et al., 1992); hence, this process appears to induce
no aggregation of GePc.
The time dependence of GePc distribution among tumour
and selected normal tissues is shown in Figures 5 and 6 for
injected doses of 0.76 and 1.52mgkg-' b.w. respectively.
Particular attention was paid to muscle, which represents the
peritumoral tissue in our animal model, and skin, since
cutaneous photosensitivity is often an undesired side-effect of
PDT (Dougherty, 1987). We also analysed the GePc content
in liver and spleen, since the components of the reticuloen-
dothelial system exhibit a high affinity for systemically
injected lipid-type colloidal particles (Scherphof et al., 1989);
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Figure 4 Effect of time on the clearance of GePc from sera of
Balb/c mice bearing an MS-2 fibrosarcoma. The mice were
injected intravenously with 0.76 (0) or 1.52 (0) mgkg-'
phthalocyanine. Average of at least five independently analysed
mice at each time.
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Figure 7, the photoinduced tumour necrotic area is about
22mm2 after 3 h and undergoes no significant further inc-
rease at longer time intervals.
The main ultrastructural features of untreated MS-2
fibrosarcoma are essentially identical to those previously pub-
lished (Zhou et al., 1988) as regards both malignant cells
(Figure 8a) and the blood vessels (Figure 8b). At 30min after
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Figure 5 Biodistribution of GePc in tumour ( ) and selected
normal tissues ( _, spleen; LII, liver; , muscle; =I
skin) of Balb/c mice bearing an MS-2 fibrosarcoma at various
times after i.v. injection of a 0.76 mg kg-' photosensitiser dose.
Average of at least five independently analysed mice at each
time.
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moreover, hydrophobic photosensitisers are largely
eliminated from the organism via the bile-gut patwhay (Jori,
1987).
The histograms in Figures 5 and 6 give the GePc recoveries
(plus standard deviation) for at least five independently
examined mice at each time point. It was not possible to
extend our investigations beyond 1 week after GePc injection
owing to exceedingly large tumour size and possible death of
the animals.
At all times examined minimal amounts of GePc (maxi-
mum 0.15 ytg per g of tissue at 24 h after injection of
1.52 mgkg-') were recovered from brain. Thus, any toxic
effect of GePc on the central nervous system is unlikely.
Phototherapeutic studies
The PDT efficacy of GePc was tested upon injection of a
1.52mgkg-' b.w. photosensitiser dose. On the basis of the
pharmacokinetic data, the tumour mass was irradiated at
24 h after GePc administration, which corresponds with the
largest accumulation of the phthalocyanine.
Ten mice bearing the MS-2 fibrosarcoma were treated by
the PDT protocol detailed in the Materials and methods
section; in all cases, tumour damage became clearly visible
within c. 6 h from the end of irradiation, leading to the onset
of necrotic areas, decrease in the tumour mass, ulceration
and eschar formation. In a parallel set ofexperiments, groups
of five mice, treated by PDT as described above, were
sacrificed at different times after irradiation: as shown in
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Figure 6 Biodistribution of GePc in tumour ( and selected
normal tissues ( _, spleen; II, liver; , muscle; = ,
skin) of Balb/c mice bearing an MS-2 fibrosarcoma at various
times after i.v. injection of a 1.52 mg kg-' photosensitiser dose.
Average of at least five independently analysed mice at each
time.
Figure 7 Extent of tumour necrotic area developed at different
times after PDT of an MS-2 fibrosarcoma in the presence of
1.52mg kg-' GePc (average of five mice at each point).
a
Figure 8 a, Tumour cells of control mouse are polyhedral with a
large nucleus (N), small mitochondria (m), abundant free
ribosomes, few profiles of rough endoplasmic reticulum (RER).
b, Blood capillaries in neoplastic tissues are of continuous type.
E, endothelium; L, lumen. Bars = I gm. a, x 6,000; b,
x 7,500.
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Figure 9 Typical micrographs taken 30 min after PDT; both Figure 10 Typical micrographs obained 90 min after PDT; in
malignant (a) and endothelial (b) cells show some alterations of neoplastic (a) and endothelial (b) cells the photodamage is more
membrane systems which are partially swollen (arrows). evident. The plasma membrane of malignant cells is disrupted
Bars = 1 gLm. a, x 7,500; b, x 7,500. and the cellular organelles are not clearly distinguishable (a);
similar damage is also detectable in the endothelial wall (b). E,
endothelium; L, lumen. Bars = 1 l&m. a, x 9,000; b, x 7,500.
PDT the tumour tissue still shows an objectively compact
structure, but there is unequivocal evidence of photoinduced
damage in neoplastic cells, especially at the level of memb-
ranous systems, including Golgi apparatus, endoplasmic
reticulum and mitochondria (Figure 9a); on the other hand,
the cell nuclei and the perinuclear membrane are well pre-
served. Quite similar alterations are also evident in the cells
of the capillary endothelium (Figure 9b).
The pattern of cellular damage becomes more marked at
later times after irradiation. At 90 min several gaps are detec-
table in the plasma membrane, while the perinuclear mem-
brane becomes swollen and floccular material can be observed
in the intercellular space (Figure 10a); again, parallel changes
occur in capillaries (Figure lOb). At 3 h after PDT, several
subcellular organelles appear to be poorly identifiable and
optically empty and scattered cores of endocytoplasmic
coagulation are observed in malignant and endothelial cells
(Figure 1 la and b). Besides, the alterations of the perinuclear
membrane become very pronounced and the nuclear
chromatin is pyknotic. The organised subtissular structure is
almost completely lost after 8 h (Figure 12a and b): the
cellular borders are often undefined, and most cells are com-
pletely necrotic with pyknotic nuclei; the residual blood capil-
laries are stuffed with erythrocytes.
Discussion
Liposome-incorporated GePc appears to be endowed with a
photosensitising activity toward biological substrates at least
as high as that exhibited by other widely used tumour
photosensitisers, including haematoporphyrin and Zn(II)
phthalocyanine, at least as judged by the efficiency of tryp-
tophan photo-oxidation (Jori, 1992b). Actually, GePc in the
liposomes exists in a purely monomeric state even at
relatively large concentrations: the low dielectric constant of
the phospholipid bilayer and the presence of bulky axial
ligands must drastically weaken the intermolecular hydro-
phobic interactions which promote the aggregation of macro-
cyclic porphyrinoid compounds (Reddi & Jori, 1988).
Monomeric phthalocyanines are characterised by long-lived
triplet states and high quantum yield of photosensitised
generation of activated oxygen species. In particular, GePc
appears to perform its photosensitising action largely via the
intermediacy of singlet oxygen, as shown by (i) the
independence of the photo-oxidation rate constant over a
wide range of tryptophan concentrations, while alternative
photoreaction pathways involving a direct interaction
between the excited photosensitiser and the substrate are
concentration dependent (Foote, 1976); and (ii) the almost
822 A. SEGALLA et al.
a
bPDT OF TUMOURS WITH A NEW GE PHTHALOCYANINE
a a
b b
Figure 11 Typical micrographs taken 180 min after PDT; the
photodamage involves also the nuclei with pyknosis of the
chromatin and swelling of the perinuclear membrane (indicated
by an arrow in b). Bars = 1 tim. a, x 7,500; b, x 7,500.
40-fold enhancement of the reaction rate in D20- as com-
pared with H20-based media, as one would expect for a
predominant singlet oxygen mechanism, since the lifetime of
this transient is remarkably longer in deuterated solvents
(Gorman & Rodgers, 1992).
In spite of its high reactivity in the electronically excited
states, GePc undergoes very little photobleaching, which
would cause a permanent chemical modification, even under
extreme irradiation conditions. There are divergent opinions
as regards the role of dye photobleaching in PDT (Moan &
Berg, 1992): the often more rapid photoinduced bleaching of
the dye in peritumoral tissues (especially skin) during irradia-
tion facilitates the achievement of a selective tumour damage
while precluding a persistent photosensitivity in healthy tis-
sues; on the other hand, photobleaching decreases the
effective photosensitiser concentration in the tumour, besides
generating photodegradation products whose clearance rate
from tissues and possible toxic effects are to be defined.
Clearly, a more definite solution of the problems associated
with photosensitivity in non-tumoral areas would be
represented by a small accumulation in and/or fast elimina-
tion of the photosensitiser from normal tissues.
In actual fact, our pharmacokinetic studies indicate a low
GePc content in muscle (peritumoral tissue) and skin at all
Figure 12 Typical micrographs obtained 480 min after PDT;
both tumour (a) and endothelial (b) cells are completely necrotic.
Bars = I ,Am. a, x 9,000; b, x 6,000.
post-injection times examined by us. Even tissues such as
liver and spleen, which accumulate large concentrations of
GePc, release the phthalocyanine at a relatively fast rate; this
observation, coupled with the essentially complete disap-
pearance of GePc from serum within 1 week after administ-
ration, should guarantee against long-term undesired dark
effects or photo-effects. From this point of view, GePc has a
distinct advantage over Photofrin as appreciable amounts of
the porphyrin persist in serum, liver and spleen for several
weeks (Bellnier et al., 1989). A comparative analysis of the
time-dependent biodistribution of a variety of tumour-
localising agents suggests that their elimination is facilitated
either by the presence of structural features increasing the
polarity of the molecule or by the absence of aggregated
material (Cuomo et al., 1991). Both these properties are
associated with GePc, which is essentially monomeric (at
least in the serum) and is made less hydrophobic by the
conjugation with two cholesterol moieties.
On the other hand, the selectivity of tumour targeting by
GePc, as it is expressed by the ratio of phthalocyanine con-
centration in the MS-2 fibrosarcoma to the muscle, is similar
to that observed for other liposome-delivered phthalo-
cyanines (Cuomo et al., 1991). This could be related to the
fact that the presence of two cholesterol moieties brings
823824 A. SEGALLA et al.
about only a marginal increase (27% vs 20-24%) in the
fraction of LDL-bound GePc as compared with other hyd-
rophobic porphyrin or phthalocyanine derivatives (Kong-
shaug et al., 1990; Jori & Reddi, 1993). On the contrary, the
addition of cholesterol to the liposome carrier has been
shown to increase the amount of Zn(II) phthalocyanine
associated with LDL (up to 33%; Ginevra et al., 1990).
Thus, it appears that manipulation of the photosensitiser
molecule has a relatively minor effect on its distribution
among the components of the lipoprotein family; rather, the
photosensitiser transfer to lipoproteins is mainly controlled
by the properties of the delivery system. Even a relatively
hydrophilic tetrapyrrole, such as haematoporphyrin, becomes
associated with lipoproteins in significant amounts when it is
injected in vivo after incorporation into suitable liposomes
(Beltramini et al., 1987).
The combination of a high photosensitising activity and
high affinity for the fibrosarcoma explains the excellent PDT
efficacy of GePc. All mice that received 1.52mgkg-' GePc
showed an important response of the neoplastic lesion to our
irradiation protocol. While similar observations were made
for other tumour localisers (Marcus, 1992; Jori, 1992a), the
tumour-photodamaging process promoted by GePc presents
some unique features. In the first place, tumour necrosis
develops in a short period of time and reaches a maximal
extension at c. 3 h after the phototreatment; quite often the
extent of PDT-induced necrotic area continues to progress
for up to 12-16 h after PDT (see for example Reddi et al.,
1990). In the present case, the fast propagation rate of the
photodamage is likely to reflect the modality of GePc action
on the tumour: both malignant cells and the vascular
endothelium are heavily affected at the shortest post-
irradiation times analysed in our electron microscope studies;
in all cases, cell membranes appear to be the main target of
the photoprocess while nuclear components are affected only
at relatively long times. This would- rule out a possible
mutagenic action of PDT with the present GePc derivative.
On the whole, the time dependence of the development of
tumour necrosis in our animal model appears to be cor-
related with the GePc levels in the tumour, while for more
hydrophilic photosensitisers, such as N-aspartylchlorine e6,
which are known to induce tumour necrosis via a
predominantly vascular damage, the response of the tumour
to PDT treatment closely reflects the plasma levels of the dye
(Gomer & Ferrario, 1990). Previous studies (Zhou, 1989)
have shown that liposome-administered photosensitising dyes
preferentially affect tumour cells, where they are released by
LDLs through receptor-mediated endocytosis. The photo-
damage of blood capillaries is typically induced by hydro-
philic dyes (Reed et al., 1988; Henderson & Bellnier, 1989);
Kessel et al. (1987) proposed that these dyes are largely
transported by albumin and deposited in the extracellular
matrix. This does not appear to be the case for GePc, since
our ultracentrifugation data show that this phthalocyanine is
almost exclusively transported by lipoproteins. Therefore, the
identification of the factors controlling the modes of tumour
photosensitisation by GePc might disclose novel pathways
for PDT. It has been often stated that a simultaneous dest-
ruction of malignant cells and the tumour vasculature should
optimise the outcome of this phototherapeutic modality.
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